[go: up one dir, main page]

NO20091490L - Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer - Google Patents

Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer

Info

Publication number
NO20091490L
NO20091490L NO20091490A NO20091490A NO20091490L NO 20091490 L NO20091490 L NO 20091490L NO 20091490 A NO20091490 A NO 20091490A NO 20091490 A NO20091490 A NO 20091490A NO 20091490 L NO20091490 L NO 20091490L
Authority
NO
Norway
Prior art keywords
leukemia
tyrosine kinase
abl tyrosine
cmin
bcr
Prior art date
Application number
NO20091490A
Other languages
English (en)
Norwegian (no)
Inventor
Insa Gathmann
Francois-Xavier Mahon
Mathieu Molimard
Stephane Picard
Yanfeng Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091490(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20091490L publication Critical patent/NO20091490L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Ecology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20091490A 2006-09-22 2009-04-16 Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer NO20091490L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82662206P 2006-09-22 2006-09-22
US82827806P 2006-10-05 2006-10-05
PCT/US2007/078978 WO2008036792A2 (fr) 2006-09-22 2007-09-20 Procédé d'optimisation de traitement de la leucémie philadelphie positive avec des inhibiteurs de tyrosine kinase abl

Publications (1)

Publication Number Publication Date
NO20091490L true NO20091490L (no) 2009-06-15

Family

ID=39092883

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091490A NO20091490L (no) 2006-09-22 2009-04-16 Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer

Country Status (24)

Country Link
US (2) US20090281113A1 (fr)
EP (2) EP2251042A3 (fr)
JP (1) JP5735742B2 (fr)
KR (1) KR20090065512A (fr)
AT (1) ATE495761T1 (fr)
AU (1) AU2007299764B2 (fr)
BR (1) BRPI0717099A2 (fr)
CA (1) CA2662977A1 (fr)
CL (1) CL2007002725A1 (fr)
CY (1) CY1111356T1 (fr)
DE (1) DE602007012122D1 (fr)
DK (1) DK2068938T3 (fr)
HR (1) HRP20110250T1 (fr)
IL (1) IL197296A (fr)
MA (1) MA30786B1 (fr)
MX (1) MX2009003082A (fr)
NO (1) NO20091490L (fr)
NZ (1) NZ575113A (fr)
PL (1) PL2068938T3 (fr)
PT (1) PT2068938E (fr)
TN (1) TN2009000094A1 (fr)
TW (1) TWI398251B (fr)
WO (1) WO2008036792A2 (fr)
ZA (1) ZA200901220B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101951910B (zh) 2008-01-23 2013-07-17 诺瓦提斯公司 优化用伊马替尼治疗酪氨酸激酶受体kit介导的增殖性疾病的制药用途
JP2012510470A (ja) * 2008-12-01 2012-05-10 ノバルティス アーゲー メシル酸イマチニブを用いたフィラデルフィア陽性白血病の処置を最適化する方法
US20110046919A1 (en) * 2009-03-02 2011-02-24 Juliesta Elaine Sylvester Method for accurate measurement of enzyme activities
FR2943418A1 (fr) * 2009-03-17 2010-09-24 Centre Nat Rech Scient Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications
EP3072964A1 (fr) * 2013-11-22 2016-09-28 National Center For Child Health And Development Nouveau gène chimère atf7ip-pdgfrb pour la leucémie lymphoblastique aiguë
CN108271374B (zh) 2015-07-07 2021-09-21 科德克希思公司 具有改进的活性的新颖p450-bm3变体
IT201900008808A1 (it) 2019-06-13 2020-12-13 Univ Ca Foscari Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma
CN114994213A (zh) * 2022-06-28 2022-09-02 北京赛诺浦生物技术有限公司 一种测定人血浆中抗肿瘤药物酪氨酸激酶抑制血药浓度的试剂盒及测定方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
EP2308833A3 (fr) 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Inhibiteurs de kinase de tyrosine de protéine cyclique
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
JP2005522221A (ja) * 2002-04-17 2005-07-28 ノバルティス アクチエンゲゼルシャフト チロシンキナーゼ阻害剤に対する患者応答性の予測方法
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
RU2401265C2 (ru) 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
MY148074A (en) 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant

Also Published As

Publication number Publication date
US20170007605A1 (en) 2017-01-12
BRPI0717099A2 (pt) 2013-10-15
JP2010504353A (ja) 2010-02-12
PL2068938T3 (pl) 2011-06-30
TWI398251B (zh) 2013-06-11
US20090281113A1 (en) 2009-11-12
HK1133194A1 (en) 2010-03-19
MX2009003082A (es) 2009-04-01
ZA200901220B (en) 2010-02-24
TW200822926A (en) 2008-06-01
PT2068938E (pt) 2011-03-23
JP5735742B2 (ja) 2015-06-17
IL197296A (en) 2011-11-30
WO2008036792A3 (fr) 2008-11-13
MA30786B1 (fr) 2009-10-01
DE602007012122D1 (de) 2011-03-03
NZ575113A (en) 2012-03-30
EP2251042A2 (fr) 2010-11-17
CY1111356T1 (el) 2015-08-05
HRP20110250T1 (hr) 2011-05-31
IL197296A0 (en) 2011-08-01
AU2007299764B2 (en) 2011-10-13
TN2009000094A1 (en) 2010-08-19
EP2068938B1 (fr) 2011-01-19
CA2662977A1 (fr) 2008-03-27
DK2068938T3 (da) 2011-04-04
ATE495761T1 (de) 2011-02-15
AU2007299764A1 (en) 2008-03-27
CL2007002725A1 (es) 2008-05-16
WO2008036792A2 (fr) 2008-03-27
EP2251042A3 (fr) 2012-05-02
EP2068938A2 (fr) 2009-06-17
KR20090065512A (ko) 2009-06-22
RU2009114856A (ru) 2010-10-27

Similar Documents

Publication Publication Date Title
NO20091490L (no) Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer
EA201690111A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
HUP0302332A2 (hu) Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére
KR20050037510A (ko) 키나제 억제제를 사용하는 암 치료 방법
Savastano et al. Antioxidant therapy in idiopathic tinnitus: preliminary outcomes
KR102425655B1 (ko) 수면 개선 방법
EP1720574A4 (fr) Methode de traitement d'une croissance cellulaire anormale au moyen d'inhibiteurs c-met et m-tor
EA201071422A1 (ru) Способы лечения заболеваний, связанных с мейотическим кинезином
WO2010066891A3 (fr) Méthode de prédiction de la réponse à un traitement à l'aide d'inhibiteurs de tyrosine kinase ciblant la protéine de fusion bcr-abl chez des patients atteints de leucémie myéloïde chronique
BRPI0518795A2 (pt) mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio
RU2010101634A (ru) Способ оптимизации лечения хронического миелолейкоза с помощью ингибиторов трирозинкиназы abi
DK2196199T3 (da) Behandling af fantomfænomener
RU2020134183A (ru) Способ ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы
EA201300410A1 (ru) Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2
Abbasian et al. Sirtuin1 and Chronic Myeloid Leukemia: a Comprehensive Glance at Drug Resistance.
TW200507828A (en) Method for treatment of chemotherapy-induced diarrhea
RU2483732C2 (ru) СПОСОБ ОПТИМИЗАЦИИ ЛЕЧЕНИЯ ЛЕЙКОЗА, ПОЛОЖИТЕЛЬНОГО ПО ФИЛАДЕЛЬФИЙСКОЙ ХРОМОСОМЕ, ИНГИБИТОРАМИ Ab1-ТИРОЗИНКИНАЗЫ
Rodriguez et al. AB0165 THE ROLE OF CXCL4, CXCL8 AND GDF-15 IN SYSTEMIC SCLEROSIS
Radich The (near) miracle of therapy in chronic myeloid leukaemia.
CN102526734A (zh) 治疗年龄相关性听力损失的药物组合物及其应用
WO2010065433A1 (fr) Méthode d’optimisation du traitement de la leucémie philadelphie positive avec du mésylate d’imatinib
WO2001045690A3 (fr) Utilisation de bvdu pour inhiber la croissance de cellules hyperproliferantes
ATE312612T1 (de) Methode zur optimierung der verwendung von 6- mercaptopurin in der behandlung von immun- vermittelten gastrointestinalen störungen
Snead et al. New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided?

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application